Advertisement

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

First International Summit on Interventional Pharmacoeconomics

Advertisement

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Opening Session Panel Discussion

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Advertisement

Advertisement

Apr

11

Today In Oncology

Novel BTK and BCL2 Inhibitors Redefine CLL Treatment Across Front-Line and Relapsed Settings

Invitation to Colonoscopy vs Fecal Immunochemical Test Screening for Colorectal Cancer

Study Illuminates Disparities in Treatment Survival in Metastatic Pancreatic Ductal Adenocarcinoma

American Cancer Society Launches CEO Search

Frailty Following Chemotherapy May Be Linked to Poorer Survival in Older Women With Breast Cancer

Advertisement

© 2025 HSP News Service, L.L.C.